{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:23:14Z","timestamp":1780561394806,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jbspin.2022.105482","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T22:20:16Z","timestamp":1667514016000},"page":"105482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis: A review of the literature and discussion on current practice"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8547","authenticated-orcid":false,"given":"Casper","family":"Webers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2022.105482_bib0265","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Compan","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0270","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","article-title":"Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0275","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","article-title":"Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease","volume":"30","author":"Navarro-Comp\u00e1n","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0280","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.111337","article-title":"Dosage adjustment of anti-tumor necrosis factor-\u03b1 inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice","volume":"39","author":"Paccou","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0285","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.23167","article-title":"Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment","volume":"58","author":"Breban","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105482_bib0290","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"10.1016\/j.jbspin.2022.105482_bib0295","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0300","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0394632016656013","article-title":"Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population","volume":"29","author":"Li","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratacos","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105482_bib0310","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20929441","article-title":"Disease activity guided stepwise tapering or discontinuation of rhTNFR:Fc, an etanercept biosimilar, in patients with ankylosing spondylitis: a prospective, randomized, open-label, multicentric study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0315","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-eular.1354","article-title":"Feasibility of progressive anti-TNF tapering in axial spondyloarthritis patients in low disease activity: results from the multicenter non-inferiority prospective randomized controlled trial spacing","volume":"80","author":"Lukas","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0320","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","article-title":"Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial","volume":"81","author":"Michielsens","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0325","first-page":"1","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","author":"Ruwaard","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0330","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/annrheumdis-2022-eular.1061","article-title":"OP0022\u00a0\u2013\u00a0Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a randomised, open-label, equivalence trial","volume":"81","author":"Uhrenholt","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0335","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landewe","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0340","unstructured":"Merck S, Dohme LLC. Golimumab (MK-8259 SCH900259) treatment withdrawal in participants with non-radiographic axial spondyloarthritis (GO-BACK) (MK-8259-038). https:\/\/ClinicalTrials.gov\/show\/NCT032537962021."},{"key":"10.1016\/j.jbspin.2022.105482_bib0345","doi-asserted-by":"crossref","first-page":"105422","DOI":"10.1016\/j.jbspin.2022.105422","article-title":"Correspondence between patient-reported flare and disease activity score variation in axial spondyloarthritis: a 12-months web-based study","volume":"89","author":"Costantino","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2022.105482_bib0350","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.berh.2015.09.006","article-title":"De-intensifying treatment in established rheumatoid arthritis (RA): why, how, when and in whom can DMARDs be tapered?","volume":"29","author":"Fautrel","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0355","first-page":"2398","article-title":"Tapering of TNF inhibitors in axial spondyloarthritis in routine care\u00a0\u2013\u00a02-year clinical and MRI outcomes and predictors of successful tapering","volume":"61","author":"Wetterslev","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105482_bib0360","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2022-eular.654","article-title":"POS0298 - Occurrence and prediction of flare after tapering of TNF inhibitors in patients with axial spondyloarthritis","volume":"81","author":"Wetterslev","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0365","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13075-019-1943-6","article-title":"Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study","volume":"21","author":"Park","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105482_bib0370","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","article-title":"A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study","volume":"75","author":"Zavada","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0375","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1136\/annrheumdis-2015-208317","article-title":"Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study","volume":"75","author":"Kievit","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0380","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105482_bib0385","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105482_bib0390","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.38014","article-title":"Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare","volume":"65","author":"Haibel","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105482_bib0395","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","article-title":"Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0400","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","article-title":"Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2-year data of the ESTHER trial","volume":"71","author":"Song","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0405","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landewe","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2022.105482_bib0410","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2020-eular.1322","article-title":"Etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: results of re-embark, an open-label, phase iv trial","volume":"79","author":"Van Den Bosch","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0415","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","article-title":"Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: Efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0420","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/annrheumdis-2021-eular.1547","article-title":"POS0229\u00a0\u2013\u00a0Disease activity and inflammation following withdrawal of certolizumab pegol treatment in AXIAL spondyloarthritis patients who did not experience flares during the C-Optimise Study","volume":"80","author":"Gensler","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0430","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/rheumatology\/keab741","article-title":"Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study","volume":"61","author":"Michielsens","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2022.105482_bib0435","first-page":"592","article-title":"Low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis","volume":"34","author":"Park","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0440","first-page":"03","article-title":"Risk of flare after tapering or withdrawal of b-\/tsDMARDs in patients with RA or axSpA: a systematic review and meta-analysis","volume":"3","author":"Uhrenholt","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2022.105482_bib0445","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02188-x","article-title":"Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis","volume":"22","author":"Vinson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105482_bib0450","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","author":"Ramiro","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0455","first-page":"2700","article-title":"Efficacy outcomes following etanercept withdrawal by sustained remission status in patients with Nr-axSpA: results from RE-EMBARK","volume":"72","author":"Van Den Bosch","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0460","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-013-2372-6","article-title":"Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients","volume":"33","author":"De Stefano","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0465","first-page":"R439","article-title":"Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study","volume":"4","author":"Van Rossen","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.jbspin.2022.105482_bib0470","first-page":"4076","article-title":"Predictors of maintaining inactive disease after etanercept withdrawal, and regaining inactive disease status after flare and retreatment, in adults with non-radiographic axial spondyloarthritis: results from RE-EMBARK","volume":"72","author":"Van Den Bosch","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0475","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10067-017-3763-x","article-title":"Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years\u2019 following-up study","volume":"37","author":"Zhao","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0480","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-019-1873-3","article-title":"Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study","volume":"21","author":"Moreno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2022.105482_bib0485","first-page":"174","article-title":"Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice","volume":"33","author":"Arends","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0490","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/msc.1367","article-title":"Dose reduction of biologic therapy in inflammatory arthritis: a qualitative study of patients\u2019 perceptions and needs","volume":"17","author":"Hewlett","year":"2019","journal-title":"Musculoskelet Care"},{"key":"10.1016\/j.jbspin.2022.105482_bib0495","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/03009742.2018.1533034","article-title":"Dose reduction of biological therapies for inflammatory rheumatic diseases: what do patients think?","volume":"48","author":"Wallis","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0500","first-page":"588","article-title":"POS0638\u00a0\u2013\u00a0Recommendations for cost-effective use of biological and targeted synthetic DMARDs in inflammatory arthritis: results from an international Delphi Study","volume":"81","author":"Van der Togt","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105482_bib0505","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2022.105482_bib0510","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105482_bib0515","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2022.105482_bib0520","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","author":"Webers","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:30:12Z","timestamp":1761150612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X22001427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1297319X22001427"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105482","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis: A review of the literature and discussion on current practice","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105482"}}